B-cell targeted therapeutics in clinical development

Arthritis Research and Therapy

Volumn 15, Issue SUPPL.1, 2013, Pages

  Blüml, Stephan ^a,b   McKeever, Kathleen ^c   Ettinger, Rachel ^c   Smolen, Josef ^a,b   Herbst, Ronald ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Neurological Center Rosenhuegel   (Austria)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 557; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; BLISIBIMOD; CD19 ANTIGEN; CD20 ANTIBODY; CD22 ANTIGEN; CDP 7657; EPRATUZUMAB; MEDI 551; MEDI 570; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NN 8828; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; TABALUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VELTUZUMAB;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B CELL LEUKEMIA; B LYMPHOCYTE; CELL MATURATION; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION REJECTION; LYMPHOCYTE DIFFERENTIATION; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PATIENT SELECTION; PEMPHIGUS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84875873134     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3906     Document Type: Review

References (209)

1. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8:363-372.
2. Obukhanych TV, Nussenzweig MC. T-independent type II immune responses generate memory B cells. J Exp Med 2006, 203:305-310.
3. Pillai S, Cariappa A, Moran ST. Positive selection and lineage commitment during peripheral B-lymphocyte development. Immunol Rev 2004, 197:206-218.
4. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009, 45:144-158.
5. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002, 20:253-300.
6. Hayakawa K, Hardy RR, Honda M, Herzenberg LA, Steinberg AD, Herzenberg LA. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci USA 1984, 81:2494-2498.
7. Hayakawa K, Hardy RR. Normal, autoimmune, and malignant CD5+ B cells: the Ly-1 B lineage?. Annu Rev Immunol 1988, 6:197-218.
8. Hardy RR, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T. Rheumatoid factor secretion from human Leu-1+ B cells. Science 1987, 236:81-83.
9. Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987, 236:77-81.
10. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 2011, 11:34-46.
11. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985, 314:537-539.
12. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005, 238:67-75.
13. Chen X, Jensen PE. The role of B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz) 2008, 56:77-83.
14. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995, 13:127-149.
15. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004, 41:599-613.
16. Zhong G, Reis e Sousa C, Germain RN. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. J Exp Med 1997, 186:673-682.
17. Cassell DJ, Schwartz RH. A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation. J Exp Med 1994, 180:1829-1840.
18. Yan J, Wolff MJ, Unternaehrer J, Mellman I, Mamula MJ. Targeting antigen to CD19 on B cells efficiently activates T cells. Int Immunol 2005, 17:869-877.
19. Morris SC, Lees A, Finkelman FD. In vivo activation of naive T cells by antigen-presenting B cells. J Immunol 1994, 152:3777-3785.
20. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007, 104:20878-20883.
21. O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A. Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005, 174:3781-3788.
22. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167:4710-4718.
23. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008, 20:332-338.
24. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today 1997, 18:343-350.
25. Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, Tuma E, Giese T, Ellwart JW, Endres S, Hartmann G. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004, 172:954-963.
26. Tumanov AV, Kuprash DV, Mach JA, Nedospasov SA, Chervonsky AV. Lymphotoxin and TNF produced by B cells are dispensable for maintenance of the follicle-associated epithelium but are required for development of lymphoid follicles in the Peyer's patches. J Immunol 2004, 173:86-91.
27. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, O'Connor RA, Anderton SM, Bar-Or A, Fillatreau S, Gray D. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012, 209:1001-1010.
28. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, O'Brien CA. RANKL expression by B lymphocytes contributes to ovariectomyinduced bone loss. J Biol Chem 2012,
29. Heider U, Zavrski I, Jakob C, Bangeroth K, Fleissner C, Langelotz C, Possinger K, Hofbauer LC, Viereck V, Sezer O. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. J Cancer Res Clin Oncol 2004, 130:469-474.
30. Yeo L, Toellner KM, Salmon M, Filer A, Buckley CD, Raza K, Scheel-Toellner D. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011, 70:2022-2028.
31. Jimenez-Boj E, Redlich K, Turk B, Hanslik-Schnabel B, Wanivenhaus A, Chott A, Smolen JS, Schett G. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 2005, 175:2579-2588.
32. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
33. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997, 186:1749-1756.
34. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
35. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharideactivated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001, 167:1081-1089.
36. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007, 178:6092-6099.
37. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
38. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti- CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837.
39. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002, 99:754-758.
40. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
41. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003, 48:455-459.
42. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007, 12:898-910.
43. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-26740.
44. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010, 335:213-222.
45. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007, 67:8882-8890.
46. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006, 103:4005-4010.
47. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K. Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 2007, 44:3122-3131.
48. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008, 13:954-966.
49. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010, 28:2853-2858.
50. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008, 59:237-250.
51. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232. RAVE-ITN Research Group.
52. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DREuropean Vasculitis Study Group Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220. Jayne DREuropean Vasculitis Study Group.
53. Pitashny M, Shoenfeld Y. B cell depletion in autoimmune rheumatic diseases. Autoimmun Rev 2005, 4:436-441.
54. Levesque MC, St Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008, 121:13-21. quiz 22-23.
55. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620.
56. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007, 122:139-145.
57. Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK, Kallenberg CG, Bootsma H. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjogren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011, 63:1116-1123.
58. Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol 2011, 38:633-641.
59. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:2377-2386.
60. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ, Sanz I, Anolik JH. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 2009, 182:5982-5993.
61. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Taoufik Y. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011, 63:3692-3701.
62. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010, 62:1273-1279.
63. Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011, 25:535-548.
64. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P, Rituximab Consensus Expert Committee Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920. Rituximab Consensus Expert Committee.
65. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X, AutoImmunity and Rituximab registry and French Society of Rheumatology Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632. AutoImmunity and Rituximab registry and French Society of Rheumatology.
66. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009, 60:3225-3228.
67. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
68. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012, 64:3043-3051.
69. Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009, 361:1081-1087.
70. Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009, 361:1075-1080.
71. Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2012, 33:388-396.
72. Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011, 118:6769-6771.
73. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, Sarbagil-Maman H, Paran D, Caspi D, Elkayam O. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011, 29:1643-1648.
74. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
75. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
76. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44:1542-1545.
77. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
78. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006, 54:3612-3622.
79. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008, 67:1724-1731.
80. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008, 35:826-833.
81. Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010, 25:3586-3592.
82. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harle JR, Hot A, Kahn JE, Lambotte O, Larroche C, Leone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010, 62:2458-2466.
83. Jonsdottir T, Gunnarsson I, Mourao AF, Lu TY, van Vollenhoven RF, Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford) 2010, 49:1502-1504.
84. Jonsdottir T, Sundelin B, Welin Henriksson E, van Vollenhoven RF, Gunnarsson I. Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits. Ann Rheum Dis 2011, 70:1172-1173.
85. Moroni G, Gallelli B, Sinico RA, Romano G, Sinigaglia L, Messa P. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann Rheum Dis 2012, 71:1751-1752.
86. Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, Garcia-Hernandez F, Callejas-Rubio JL, Rascon J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA, UKBIOGEAS Registry Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012, 11:357-364. UKBIOGEAS Registry.
87. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
88. Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, Brunetta P. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011, 20:709-716.
89. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226. LUNAR Investigator Group.
90. Karnell JL, Karnell FG, Stephens GL, Rajan B, Morehouse C, Li Y, Swerdlow B, Wilson M, Goldbach-Mansky R, Groves C, Coyle AJ, Herbst R, Ettinger R. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol 2011, 187:3603-3612.
91. Herbst R, Liu Z, Jallal B, Yao Y. Biomarkers for systemic lupus erythematosus. Int J Rheum Dis 2012, 15:433-444.
92. Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjogren's syndrome. Arthritis Rheum 2010, 62:2605-2610.
93. Kallenberg CG, Vissink A, Kroese FG, Abdulahad WH, Bootsma H. What have we learned from clinical trials in primary Sjogren's syndrome about pathogenesis?. Arthritis Res Ther 2011, 13:205.
94. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J, Perdriger A, Hachulla E, Puechal X, Le Guern V, Sibilia J, Gottenberg J, Chiche L, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost J, Pers J, Nowak E, Saraux A. Tolerance and efficacy of rituximab in primary Sjogren syndrome (TEARS): results of a randomized controlled trial [abstract]. Ann Rheum Dis 2012, 71(Suppl 3):75.
95. Perez OA, Patton T. Novel therapies for pemphigus vulgaris: an overview. Drugs Aging 2009, 26:833-846.
96. Delva E, Tucker DK, Kowalczyk AP. The desmosome. Cold Spring Harb Perspect Biol 2009, 1:a002543.
97. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999, 103:461-468.
98. Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012, 132(3 Pt 2):776-784.
99. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009, 1173:683-691.
100. Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, Gilbert D, Dutot I, Roujeau JC, D'Incan M, Bedane C, Tron F, Joly P. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008, 128:2859-2869.
101. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002, 69:258-271.
102. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am 2009, 23:1163-1175.
103. McCrae K. Immune thrombocytopenia: no longer 'idiopathic'. Cleve Clin J Med 2011, 78:358-373.
104. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008, 141:149-169.
105. Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Le PQ, Janssens A, Delannoy A. Rituximab in autoimmune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med 2009, 266:484-491.
106. Bussel JB. Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematol Oncol Clin North Am 2009, 23:1329-1341.
107. Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012, 158:386-398.
108. Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard JP, Bussel J. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol 2009, 84:661-665.
109. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002, 99:3872-3873.
110. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 2009, 9:889-895.
111. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W, ACTION Study Group Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, doseranging study. Arthritis Rheum 2008, 58:2652-2661. ACTION Study Group.
112. Harigai M, Tanaka Y, Maisawa S, JA21963 Study Group Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J Rheumatol 2012, 39:486-495. JA21963 Study Group.
113. Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA, Fisheleva E, Martin C, Travers H, Dummer W. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012, 64:350-359.
114. Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA, Ashrafzadeh A, Grzeschik S, Bieraugel R, Green J, Francom S, Dummer W. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 2012, 71:1289-1296.
115. Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, Bingham CO, Ashrafzadeh A, Travers H, Safa-Leathers S, Kumar S, Dummer W. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012, 64:360-370.
116. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat Rev Drug Discov 2008, 7:909-925.
117. von Budingen HC, Bar-Or A, Zamvil SS. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 2011, 23:713-720.
118. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
119. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 2012, 142:31-37.
120. Bartok B, Silverman GJ. Development of anti-CD20 therapy for multiple sclerosis. Exp Cell Res 2011, 317:1312-1318.
121. Gensicke H, Leppert D, Yaldizli O, Lindberg RL, Mehling M, Kappos L, Kuhle J. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 2012, 26:11-37.
122. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688. HERMES Trial Group.
123. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trial group Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-471. OLYMPUS trial group.
124. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
125. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 2009, 18:491-500.
126. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006, 177:362-371.
127. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
128. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009, 183:749-758.
129. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010, 62:2227-2238.
130. Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebocontrolled clinical trial. Ann Rheum Dis 2011, 70:2119-2125.
131. Sorensen PS, Drulovic J, Havrdova E, Lisby S, Graff O, Shackelford S. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) - 24-week results of a phase II study [abstract]. Presented at 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) & 15th Annual Conference of Rehabilitation in MS (RIMS) 2010, Gothenburg, Sweden, October 13-16.
132. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:572-577.
133. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995, 3:39-50.
134. Sato S, Steeber DA, Tedder TF. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci USA 1995, 92:11558-11562.
135. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005, 102:15178-15183.
136. Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005, 88:1-50.
137. Walker JA, Smith KG. CD22: an inhibitory enigma. Immunology 2008, 123:314-325.
138. Han K, Kim Y, Lee J, Lim J, Lee KY, Kang CS, Kim WI, Kim BK, Shim SI, Kim SM. Human basophils express CD22 without expression of CD19. Cytometry 1999, 37:178-183.
139. Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti- CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom 2009, 76:237-248.
140. Acon-Laws M, Bayerl MG, Ehman C, Malysz J, Boyer C. Basophils and plasmacytoid dendritic cells are potential sources for error in flow cytometric monitoring of patients receiving anti-CD22 therapies. AKA not all anti-CD22 antibodies are created equal. Am J Hematol 2011, 86:891-892.
141. Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB, Hansen HJ. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1995, 32:1413-1427.
142. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007, 44:1331-1341.
143. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003, 9(10 Pt 2):3982S-3990S.
144. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006, 8:R129.
145. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006, 8:R74.
146. Wallace D, Hobbs K, Houssiau F, Strand V, Tak P, Wegener W, Kelley L, Barry A. Randomized controlled trials of epratuzumab (anti-CD22 mAb targeting B-cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients [abstract]. Ann Rheum Dis 2008, 67(Suppl 2):212.
147. Strand V, Gordon C, Kalunian K, Coteur G, Barry A, Keininger D, Wegener W, Petri M. Randomized controlled trials (RCTs) of epratuzumab (anti-CD22 mAb targeting B-cells) show meaningful improvements in health related-quality of life (HRQOL) in SLE patients (pts) with high disease activity and low baseline (BL) self-report measures [abstract]. Ann Rheum Dis 2008, 67(Suppl 2):212.
148. Petri M, Hobbs K, Gordon C, Strand V, Wallace D, Kelley L, Wegener W, Barry A. Randomized controlled trials (RCTs) of epratuzumab (anti-CD22 mAb targeting B-cells) reveal clinically meaningful improvements in patients (pts) with moderate/severe SLE flares [abstract]. Ann Rheum Dis 2008, 67(Suppl 2):53.
149. Wallace DJ, Kalunian KC, Petri MA, Strand V, Kilgallen B, Kelley L, Gordon CP. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM™, a phase IIb study [abstract]. Ann Rheum Dis 2010, 69(Suppl 3):559.
150. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005, 105:4390-4398.
151. Suryani S, Fulcher DA, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, Gibson J, Williams A, Tangye SG. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 2010, 115:519-529.
152. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, doubleblind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210.
153. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, Villanacci V, Plebani A, Knowles DM, Rescigno M, Cerutti A. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007, 26:812-826.
154. Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998, 188:1691-1703.
155. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001, 97:1817-1822.
156. Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, Ettinger R. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 2007, 179:5886-5896.
157. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, Chan TD, Palendira U, Bustamante J, Boisson-Dupuis S, Choo S, Bleasel KE, Peake J, King C, French MA, Engelhard D, Al-Hajjar S, Al-Muhsen S, Magdorf K, Roesler J, Arkwright PD, Hissaria P, Riminton DS, Wong M, Brink R, Fulcher DA, Casanova JL, Cook MC, Tangye SG. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010, 207:155-171.
158. Bryant VL, Ma CS, Avery DT, Li Y, Good KL, Corcoran LM, de Waal Malefyt R, Tangye SG. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007, 179:8180-8190.
159. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, Leonard WJ, Lipsky PE. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005, 175:7867-7879.
160. Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008, 223:60-86.
161. Yoon SO, Zhang X, Berner P, Choi YS. IL-21 and IL-10 have redundant roles but differential capacities at different stages of plasma cell generation from human germinal center B cells. J Leukoc Biol 2009, 86:1311-1318.
162. Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007, 178:2872-2882.
163. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Berard N. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
164. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, Brink R, Mackay F, Hodgkin PD, Tangye SG. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003, 112:286-297.
165. Zacks Equity Research CHMP Backs Benlysta 2011, Zacks Investment Research, Zacks Equity Research., http://www.zacks.com
166. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
167. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930. BLISS-76 Study Group.
168. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731. BLISS-52 Study Group.
169. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, on behalf of the BLISS-52 and BLISS-76 Study Groups Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012, 71:1833-1838. on behalf of the BLISS-52 and BLISS-76 Study Groups.
170. Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther 2012, 34:1006-1022.
171. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol 2010, 22:732-739.
172. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302.
173. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150.
174. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009, 18:547-555.
175. Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 2010, 99:524-538.
176. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011, 63:1793-1803.
177. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011, 63:1782-1792.
178. Fernandez L, Salinas GF, Rocha C, Carvalho-Pinto CE, Yeremenko N, Papon L, Medema JP, Combe B, Morel J, Baeten D, Hahne M. The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis 2012,
179. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008, 26:57-79.
180. Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009, 119:2052-2061.
181. Caruso R, Botti E, Sarra M, Esposito M, Diluvio L, Giustizieri ML, Pacciani V, Mazzotta A, Campione E, Macdonald TT, Chimenti S, Pallone F, Costanzo A, Monteleone G. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009, 15:1013-1015.
182. Rasmussen TK, Andersen T, Hvid M, Hetland ML, Horslev-Petersen K, Stengaard-Pedersen K, Holm CK, Deleuran B. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 2010, 37:2014-2020.
183. Kang KY, Kim HO, Kwok SK, Ju JH, Park KS, Sun DI, Jhun JY, Oh HJ, Park SH, Kim HY. Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011, 13:R179.
184. Tzartos JS, Craner MJ, Friese MA, Jakobsen KB, Newcombe J, Esiri MM, Fugger L. IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol 2011, 178:794-802.
185. Dolff S, Abdulahad WH, Westra J, Doornbos-van der Meer B, Limburg PC, Kallenberg CG, Bijl M. Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R157.
186. Gottenberg JE, Dayer JM, Lukas C, Ducot B, Chiocchia G, Cantagrel A, Saraux A, Roux-Lombard P, Mariette X. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2012, 71:1243-1248.
187. Maurer MF, Garrigues U, Jaspers SR, Meengs B, Rixon MW, Stevens BL, Lewis KB, Julien SH, Bukowski TR, Wolf AC, Hamacher NB, Snavely M, Dillon SR. Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies. MAbs 2012, 4:69-83.
188. Chittasupho C, Siahaan TJ, Vines CM, Berkland C. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Ther Deliv 2011, 2:873-889.
189. Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Drager R, Eibel H, Fischer B, Schaffer AA, Mages HW, Kroczek RA, Peter HH. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003, 4:261-268.
190. Dong C, Temann UA, Flavell RA. Cutting edge: critical role of inducible costimulator in germinal center reactions. J Immunol 2001, 166:3659-3662.
191. Law C, Grewal I. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Therapeutic Targets of the TNF Superfamily (Advances in Experimental Medicine and Biology Volume 647) 2009, 8:36. New York, NY: Landes Bioscience and Springer Science+Business Media, Grewal I.
192. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993, 72:291-300.
193. Farrington M, Grosmaire LS, Nonoyama S, Fischer SH, Hollenbaugh D, Ledbetter JA, Noelle RJ, Aruffo A, Ochs HD. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA 1994, 91:1099-1103.
194. Alaaeddine N, Hassan GS, Yacoub D, Mourad W. CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol 2012, 2012:490148.
195. Sullivan BA, Green CL, Zhang M, Abbott C, Belouski S, Thomas G, Gorski K. A flow cytometric receptor occupancy assay demonstrates dose-dependent blockade of B7RP-1 by AMG 557 on circulating B cells from SLE subjects [abstract]. Arthritis Rheum 2010, 62(Suppl 10):1141.
196. Hu YL, Metz DP, Chung J, Siu G, Zhang M. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol 2009, 182:1421-1428.
197. Kawamoto M, Harigai M, Hara M, Kawaguchi Y, Tezuka K, Tanaka M, Sugiura T, Katsumata Y, Fukasawa C, Ichida H, Higami S, Kamatani N. Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production. Arthritis Res Ther 2006, 8:R62.
198. Carlesso G, Taylor D, Herbst R. Targeting inducible T-cell co-stimulator in autoimmune diseases - new evidence supporting its critical function in the maintenance of secondary lymphoid tissue architecture. Eur Musculoskeletal Rev 2011, 6:248-252.
199. Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Davila M, Langer F, Amaya M, Garber E, Francis JL, Hsu YM, Amirkhosravi A. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010, 185:1577-1583.
200. Wakefield I, Peters C, Burkly L, Garber E, Ferrant J, Taylor F, Su L. CDP7657, a monovalent Fab PEG anti-CD40L antibody, inhibits immune responses in both HuSCID mice and non-human primates. [abstract]. Arthritis Rheum 2010, 62(Suppl 10):1245.
201. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337.
202. Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010, 107:4658-4663.
203. Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011, 7:170-178.
204. Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med 2011, 3:101ra92.
205. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
206. Voll RE, Alexander T, Peukert R, Rubbert A, Rech J, Braun T, Wiesener M, Eckardt K-U, Hoyer B, Taddeo A, Reisch A, Burmester G-R, Radbruch A, Schett G, Hiepe F. Successful treatment of refractory SLE patients with the proteasome inhibitor Bortezomib - a case series [abstract]. Presented at the European League Against Rheumatism (EULAR) Conference 2012, Berlin, Germany, June 6-9.
207. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006, 180:63-70.
208. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010, 67:707-714.
209. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JW, van den Berg WB, Joosten LA. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011, 63:1507-1516.